Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: clarithromycin Clear all
Completed Phase 2 Interventional

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

NCT00006219
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
clarithromycin, prasterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

NCT05965570
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Clarithromycin
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY2835219 in Participants With Cancer

NCT02117648
View directory record Official record
Conditions
Neoplasm, Neoplasm Metastasis
Interventions
Abemaciclib, Clarithromycin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)

NCT00336505
View directory record Official record
Conditions
Pneumonia
Interventions
Cethromycin, Clarithromycin
Drug
Lead sponsor
Advanced Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Woodridge, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Clarithromycin for the Treatment of Hypersomnia

NCT01146600
View directory record Official record
Conditions
Hypersomnia, Idiopathic Hypersomnia, Narcolepsy
Interventions
Clarithromycin followed by placebo, Placebo then Clarithromycin
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.

NCT00774644
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin 500mg
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients

NCT00002140
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Berkeley, California • Mill Valley, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

NCT06227832
View directory record Official record
Conditions
Healthy Adults
Interventions
KP-001, Metformin, Midazolam, Clarithromycin
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

NCT02807051
View directory record Official record
Conditions
Drug Interaction Study
Interventions
Pacritinib, Clarithromycin, Pacritinib and Clarithromycin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

NCT00001030
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

NCT00002336
View directory record Official record
Conditions
Mycobacterium Avium-intracellular Infection, HIV Infections
Interventions
Clarithromycin
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
22
States / cities
Tucson, Arizona • Fresno, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

NCT01745588
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, stem cell, Dexamethasone, Clarithromycin
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
10
States / cities
Basking Ridge, New Jersey • New Brunswick, New Jersey • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

NCT01836198
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2409021, Gemfibrozil, Ketoconazole, Clarithromycin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions

NCT00601315
View directory record Official record
Conditions
Infection
Interventions
Clarithromycin
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

NCT00000794
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Sulfadiazine, Clarithromycin, Atovaquone, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants

NCT02912234
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Clarithromycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

NCT00002192
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Anderson Clinical Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 3 Interventional

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

NCT00645086
View directory record Official record
Conditions
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).
Interventions
clarithromycin extended-release tablets, clarithromycin immediate-release tablets
Drug
Lead sponsor
Abbott
Industry
Eligibility
40 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
135
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 122 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis

NCT00205634
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Biaxin ( clarithromycin)
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
6 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects

NCT02080780
View directory record Official record
Conditions
CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Interventions
Clarithromycin XL, 2% Diltiazem
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

NCT02286635
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deflazacort and rifampin, Deflazacort and Clarithromycin
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 17, 2026, 6:07 AM EDT
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia

NCT00336544
View directory record Official record
Conditions
Pneumonia
Interventions
Cethromycin, Clarithromycin
Drug
Lead sponsor
Advanced Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Woodridge, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 17, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions

NCT00840411
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 17, 2026, 6:07 AM EDT